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Abstract: Chemotherapy-induced nausea and vomiting (CINV) in cancer patients places a 
signiﬁ  cant burden on patients’ function and quality of life, their families and caregivers, and 
healthcare providers. Despite the advances in preventing CINV, a substantial proportion of 
patients experience persistent nausea and vomiting. Nabilone, a cannabinoid, recently received 
Food and Drug Administration approval for the treatment of the nausea and vomiting in patients 
receiving cancer chemotherapy who fail to achieve adequate relief from conventional treatments. 
The cannabinoids exert antiemetic effects via agonism of cannabinoid receptors (CB1 and CB2). 
Clinical trials have demonstrated the beneﬁ  ts of nabilone in cancer chemotherapy patients. Use 
of the agent is optimized with judicious dosing and selection of patients.
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The burden of chemotherapy-induced nausea 
and vomiting
In the absence of preventive therapy, 70%–80% of cancer patients receiving chemo-
therapy experience associated nausea and vomiting (Morran et al 1979; Jenns 1994). 
Chemotherapy-induced nausea and vomiting (CINV) and its side effects imposes a 
burden on patients, clinicians, and the healthcare system (Vanscoy et al 2005; Wiser 
and Berger 2005). Of all the side effects of chemotherapy, CINV remains one of the 
most dreaded by patients (Sun et al 2004). Patients report a substantial negative impact 
of CINV on their ability to complete activities of daily living, obtain adequate rest, 
participate in social activities, and perform work (Lee et al 2005; Wiser and Berger 
2005). Further, CINV can have deleterious physiologic effects, including metabolic 
derangements, malnutrition, and esophageal tears, among others (Wiser and Berger 
2005; National Comprehensive Cancer Network 2006). In up to 30% of patients, 
CINV is so distressing that consideration is given to discontinuing treatment, which 
underscores the need for effective control of the nausea and vomiting associated with 
chemotherapy (Wiser and Berger 2005).
The introduction of 5-hydroxytryptamine-3 (5-HT3) receptor antagonists has 
had a dramatic effect on preventing CINV in cancer patients (Abrahm 2005). With 
clinical experience, however, it has become apparent that while these agents are 
effective for controlling acute CINV, they are ineffective agents for delayed nausea 
(Hickok et al 2003; Kris et al 2006). The substance P/neurokinin 1 (NK1) receptor 
antagonist, aprepitant, augments the antiemetic action of 5-HT3 receptor antagonists 
and corticosteroids such as dexamethasone. The most effective way of controlling 
delayed nausea and vomiting is to prevent the acute phase; as such, the addition of 
aprepitant to antiemetic regimens has assisted clinicians in controlling both acute and 
delayed CINV (Schwartzberg 2006). The recently revised American Society of Clinical 
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for Supportive Care in Cancer (MASCC), reﬂ  ect the efﬁ  cacy 
of aprepitant for prevention of delayed CINV due to highly 
emetogenic chemotherapy, recommending its use with a cor-
ticosteroid and against the use of 5-HT3 receptor antagonists 
for this purpose (Gralla 2005; Kris et al 2006).
Despite the augmentation of antiemetic activity provided 
by aprepitant, a substantial proportion of patients receiving 
ﬁ  rst-line therapy continue to experience persistent delayed 
CINV. Poli-Bigelli and colleagues reported their efﬁ  cacy 
ﬁ  ndings from a clinical trial involving 523 evaluable subjects 
who were receiving high-dose cisplatin-based chemotherapy 
(Poli-Bigelli et al 2005). Compared with standard therapy 
(5-HT3 receptor antagonist and a corticosteroid), the 
aprepitant-containing regimen (combined with a 5-HT3 
receptor antagonist and a corticosteroid) was signiﬁ  cantly 
(p   0.001) more effective in achieving complete control, 
deﬁ  ned as no emesis and no rescue therapy. The investigators’ 
secondary analyses revealed persistent delayed nausea in 
nearly half (47%) of the patients, however, and signiﬁ  cant 
delayed nausea in more than one of every four patients. 
Delayed emesis occurred in 28% of patients. Overall, total 
control was documented in less than half (44%) of patients.
Anticipatory nausea and vomiting also represents a sig-
niﬁ  cant problem among cancer patients undergoing chemo-
therapy. Although the etiology is likely to be multifactorial, 
one major cause is thought to be classic or Pavlovian con-
ditioning (Stockhorst et al 1993) due to incomplete control 
of post-treatment nausea (Morrow et al 1998). Anticipatory 
nausea occurs in 29% of chemotherapy patients, and antici-
patory vomiting occurs in 11% of patients about to undergo 
chemotherapy (Morrow et al 1998; Roscoe et al 2000). 
Despite improvements in overall CINV with the introduc-
tion of 5-HT3 receptor antagonist medications, the incidence 
of anticipatory nausea and vomiting has remained the same 
(Morrow et al 1998).
The high prevalence of CINV in cancer patients receiving 
chemotherapy, the burden imposed on patients, and the failure 
of ﬁ  rst-line and conventional antiemetic therapies to provide 
adequate control of nausea and vomiting, particularly delayed 
events, indicate an ongoing need for additional treatment 
options. Combining agents with different mechanisms of 
action (MOA) may be the optimal approach to management 
of CINV (National Cancer Institute 2006).
The use of cannabis to self-treat CINV has been known 
for several years (Vinciguerra et al 1988), and with recent 
improvements in our understanding of the physiology 
underlying cannabis effects, renewed efforts are underway 
to identify safe and effective pharmaceutical cannabinoids. 
A recent systematic review found evidence that cannabinoids 
were a rational option for CINV (Tramér et al 2001). This 
paper examines the clinical evidence for nabilone, a synthetic 
cannabinoid recently approved in the United States for the 
treatment of CINV.
Scientiﬁ  c rationale for the use 
of the cannabinoids in CINV
Since the definitive identification of cannabinoid (CB) 
receptors in humans, a better understanding of the science 
behind the effects of exogenous cannabinoids has emerged. 
Two CB receptors have been identiﬁ  ed in humans (CB1 and 
CB2) which are recognized exclusively by cannabinoids. 
(Howlett et al 2002; Martin and Wiley 2004). The CB1 
receptor is present in high densities in areas of the central 
nervous system (CNS), and it is the interaction between 
nabilone and this receptor and its signaling pathways that 
appears to be responsible for the antiemetic effects of the 
agent. Endocannabinoids – endogenous cannabinoid ligands 
that act on CB receptors – exert complex effects, including 
the modulation of neurotransmitters known to be involved 
in CINV (Howlett et al 2002; Martin and Wiley 2004). More 
speciﬁ  cally, endocannabinoids activate the pre-synaptic CB1 
receptor, inhibiting release of both excitatory and inhibitory 
neurotransmitters in the CNS and peripheral nervous sys-
tem (ie, glutamate and gamma aminobutyric acid [GABA], 
respectively) (Schlicker and Kathmann 2001; Howlett et al 
2002). The effect of endocannabinoids is not solely inhibi-
tory in nature; however, as an initial inhibitory effect may 
trigger increased release of neurotransmitters further along 
the pathway, thus inhibitory and excitatory effects may be 
observed.
The antiemetic effects of the endocannabinoid system 
appear to be produced by a multi-step process in which 
the CB1 ligands act as retrograde synaptic messengers 
(Diana and Mart 2004). In this “reverse signaling” process, 
neurotransmitters released from the pre-synaptic neuron 
activate the post-synaptic receptors. In turn, the activated 
post-synaptic neuron releases endocannabinoids such as 
anandamide (Freund et al 2003; Navari 2003; Piomelli 2003) 
These endogenous CB1 ligands then diffuse back and bind 
to the pre-synaptic CB1 receptor (Piomelli 2003). Binding of 
endocannabinoids to the CB1 receptor results in activation of 
a G-protein leading to a reduction of neurotransmitter release, 
a process known as depolarization-induced suppression of 
inhibition (DSI) (Freund et al 2003; Diana and Mart 2004)
Several neurotransmitters mediate nausea and vomit-
ing, including serotonin, dopamine, GABA, glutamate, Therapeutics and Clinical Risk Management 2008:4(1) 101
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cannabinoids, and others (Andrews et al 1998; Lynch 2005). 
Antagonism of serotonin, dopamine, and substance P recep-
tors (5-HT3 , D2, and NK  1, respectively) produces clinically 
meaningful antiemetic effects. In contrast, it is the agonism 
of CB1 receptors, such as that produced by cannabinoid 
compounds, which results in antiemetic effects. CB agonist 
drugs circumvent the multi-step process of the endogenous 
system (Figure 1) (Croxford 2003; Navari 2003; Freund et al 
2003; Piomelli 2003; Diana and Mart 2004). In addition to 
modulatory effects on CB receptors, the CB1 agonist nabi-
lone may also indirectly and partially manipulate 5-HT3 and 
D2 receptors (Ward and Holmes 1985; Nahas et al 2002).
Speciﬁ  c areas of the brain are involved in emesis and 
nausea, including the dorsal vagal complex, particularly 
the nucleus of the solitary tract (NTS) within this complex. 
Neurons in the area postrema, which is often referred to as 
the chemoreceptor trigger zone, transmit messages regarding 
such blood-borne emetics as cytotoxic drugs to the NTS. The 
NTS also receives messages regarding abdominal irritants 
through vagal afferents. In turn, NTS neurons transmit these 
messages to the brainstem, which directs emetic behavior 
(Hornby 2001). Other areas of the brain involved in CINV 
are the higher cortical and limbic regions, where the senses 
of taste, smell, sight, and memory are modulated. Through 
descending connections with the brainstem emetic center, 
these regions can inﬂ  uence stimulation or suppression of nau-
sea and vomiting, including anticipatory nausea and vomiting 
(Grunberg 1989; Fride et al 2005). CB1 receptors are present 
Figure 1 The mechanism of action of cannabinoids. The innate cannabinoid system inhibits release of neurotransmitters via a multi-step retrograde signaling pathway. Nabilone mimics 
the action of endocannabinoids via direct activation of CB1 receptors (derived from Croxford 2003; Freund et al 2003; Navari 2003; Piomelli 2003; Diana and Mart 2004).
Abbreviations: THC, tetrahydrocannabinol.Therapeutics and Clinical Risk Management 2008:4(1) 102
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in vast quantities in the CNS, exceeding levels of nearly all 
neurotransmitter receptors, and in nearly every brain region, 
including those involved in the pathophysiology of CINV 
(Martin and Wiley 2004). CB1 receptors are therefore valid 
targets for antiemetic effects in patients with CINV.
Anticipatory nausea and vomiting is a learned response to 
chemotherapy that develops only after poor initial control of 
CINV. Studies have shown that anticipatory nausea and vom-
iting follows the theory of a Pavlovian conditioned reﬂ  ex; the 
thought of chemotherapy or other elements associated with it 
is the stimulus (Stockhorst et al 1993). The risk of developing 
this problem increases with the number of cycles received 
and may persist for some time after the completion of therapy 
(Aapro et al 2005). Anxiety may play a role in this condition 
(Morrow et al 1998), and two randomized trials have shown 
efﬁ  cacy using benzodiazepines when added to psychological 
support programs (Razavi et al 1993; Malik et al 1995). Inter-
estingly, the synthetic cannabinoid nabilone has been found 
to be effective in anxiety (Fabre and McLendon 1981). An 
animal model of anticipatory nausea and vomiting has been 
developed for the testing of cannabinoids (Parker and Kemp 
2001; Limebeer et al 2006), which has shown cannabinoids 
to be effective in anticipatory nausea, signiﬁ  cantly better than 
both placebo and ondansetron (Parker and Kemp 2006).
Efﬁ  cacy and safety of nabilone
Nabilone is a synthetic cannabinoid developed in the 1970’s 
(Lemberger and Rowe 1975) which is a potent CB1 agonist. 
Results from early clinical studies demonstrated the efﬁ  cacy, 
safety, and tolerability of nabilone in reducing the frequency 
of vomiting and lessening the severity of nausea in cancer 
patients with CINV (Herman et al 1977, 1979; Einhorn 
et al 1981). In patients (n = 13) with CINV unrelieved by 
prochlorperazine, nabilone reduced vomiting frequency and 
nausea severity in 77%; more than half of the patients experi-
enced “excellent response” to therapy or complete resolution 
of CINV (Herman et al 1977). In this study, patients were 
given either 1 mg or 2 mg nabilone every 8 hours. A more 
potent antiemetic effect was observed with the higher dose. 
Generally, the commonly occurring side effects – sedation, 
dry mouth, dizziness, and some decrease in coordination – as 
well as those that occurred less often, were mild or moderate 
in severity. More than one half of the patients reported an 
increase in appetite and food intake.
A second paper by the same authors reported on two 
double-blind, crossover trials conducted in a total of 113 
evaluable patients with severe CINV (Herman et al 1979). 
During chemotherapy cycle 1, patients received either 
2 mg nabilone or 10 mg prochlorperazine every 8 hours. 
The patients crossed over to the second drug regimen during 
the second cycle. All patients received 2 doses of antiemetic 
medication before chemotherapy for both cycles. Nabilone 
was more effective for providing complete relief of nausea 
and vomiting than was prochlorperazine (8% vs 0%), and 
signiﬁ  cantly (p   0.01) more effective for providing a partial 
response (72% vs 32%). The number of partial and com-
plete responses occurring with nabilone was signiﬁ  cantly 
(p   0.001) greater than that with prochlorperazine (80% vs 
32%). The response to nabilone in terms of reduced vomiting 
was greater on all 5 days of therapy when compared with 
Figure 2a Nabilone reduces frequency of vomiting on chemotherapy days 1 through 5. Reproduced with permission from Einhorn LH, Nagy C, Furnas B, Williams SD. 1981. 
Nabilone: An effective antiemetic in patients receiving cancer chemotherapy. J Clin Pharmacol, 21(suppl):64–69. Copyright © 1981 SAGE Publications.Therapeutics and Clinical Risk Management 2008:4(1) 103
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prochlorperazine (p   0.001), and nausea severity declined 
each day patients received nabilone. The efﬁ  cacy of nabilone 
was observed with all types of chemotherapy and regardless 
of which order patients received the agent. Nine patients 
discontinued antiemetic therapy due to development of intol-
erable side effects – 4 who were receiving prochlorperazine 
and 5 during nabilone therapy. The predominant side effects 
were similar with both drugs; however, the incidence was 
approximately doubled during nabilone therapy. Nonethe-
less, a signiﬁ  cant (p   0.001) proportion of patients preferred 
nabilone over prochlorperazine (78% vs 15%).
Einhorn and colleagues conducted a double-blind, 
randomized, cross-over study in 100 cancer patients 
(Einhorn et al 1981). These patients, most of whom received 
cisplatin-based chemotherapy for testicular cancer, received 
2 mg nabilone or 10 mg prochlorperazine every 6 hours as 
needed during chemotherapy cycle one and crossed over to 
the second drug during cycle 2. Compared with the effects 
of prochlorperazine, nabilone significantly (p   0.001) 
reduced the severity and duration of nausea and frequency of 
vomiting. In patients receiving nabilone, the mean severity 
score for nausea (1 = mild, 2 = moderate, 3 = severe nausea) 
declined from day 1 to day 3 and remained stable thereafter 
at values lower than 1. With nabilone therapy, the number 
of vomiting episodes was reduced by about 33% on all days 
of chemotherapy. Of the 20 patients who failed to complete 
the study, only 3 withdrew due to adverse effects of nabilone. 
Similar to the ﬁ  nding from Herman and associates, patients 
overwhelmingly preferred nabilone over prochlorperazine 
(60 patients [75%] vs 17 patients [17%]). Of the 60 patients 
who indicated a preference for nabilone, 46 received further 
chemotherapy and opted to continue to receive nabilone for 
a total of 76 courses of chemotherapy.
Results similar to those described above have also 
been found showing the superiority of nabilone compared 
to prochlorperazine in lung cancer patients undergoing 
chemotherapy (Ahmedazi et al 1983; Niiranen and 
Mattson 1985), but the side effect proﬁ  le of dizziness and 
disorientation demands careful patient monitoring. No 
difference was found between nabilone and metoclopramide 
in patients on cisplatin (Crawford and Buckman 1986), while 
nabilone has been found superior to alizapride in young 
patients with testicular cancer on cisplatin (Niederle 1986) 
and was superior to domperidone in another trial in which 
70% of subjects were on cisplatin (Pomeroy et al 1986). 
Mixed results have been found comparing oral nabilone 
and prochlorperazine to intravenous dexamethasone and 
metoclopramide (Cunningham et al 1988). Nabilone has even 
shown to be superior to prochlorperazine for children under-
going chemotherapy (Chan et al 1987). The effectiveness and 
tolerability of nabilone may be improved by the addition of 
dexamethasone (Niiranen and Mattson 1987).
The results of these early studies were summarized in a 
2001 systematic review of 30 studies involving cannabinoids 
(nabilone, 16 studies; dronabinol, 13 studies; levonantradol, 
1 study) compared with placebo or active control (prochlor-
perazine, metoclopramide, chlorpromazine, haloperidol, 
domperidone, and alizapride) for the treatment of CINV 
(Tramér et al 2001). Cannabinoids were more effective 
than either active control or placebo for the reduction of 
vomiting episodes and lessening of nausea severity. When 
compared with placebo (4 studies), the number needed to treat 
Figure 2b Nabilone signiﬁ  cantly reduces the severity of nausea throughout the chemotherapy cycle. Reproduced with permission from Einhorn LH, Nagy C, Furnas B, Williams 
SD. 1981. Nabilone: An effective antiemetic in patients receiving cancer chemotherapy. J Clin Pharmacol, 21(suppl):64–69. Copyright © 1981 SAGE Publications.
Grading of nausea: 1 = mild; 2 = moderate; 3 = severe.Therapeutics and Clinical Risk Management 2008:4(1) 104
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(NNT) for complete control of nausea was 8; compared with 
active control (7 studies), the NNT was 6.4. Compared with 
placebo (4 studies) and active control (6 studies), the NNT 
for complete control of vomiting was 3.3 and 8, respectively. 
Cannabinoids were shown to be well tolerated, and analysis 
demonstrated a patient preference for these agents over both 
active controls and placebo. As well, the authors commented 
that “In selected patients, cannabinoids may be useful as 
mood enhancing adjuvants for the control of chemotherapy 
related sickness”, likely referring to the possible beneﬁ  ts 
in patients with anticipatory nausea and vomiting (Tramér 
et al 2001).
Since these studies were conducted, the 5-HT3 and NK 
receptor antagonists have been developed and incorporated 
into routine clinical care protocols. Studies comparing 
nabilone to these agents either alone or in combination 
have not been done to date. Dronabinol, a synthetic form of 
tetrahydrocannabinol (the principle psychoactive ingredi-
ent in cannabis) has also been licensed as an antiemetic and 
has not been shown to be superior to ondansetron (Meiri 
et al 2007). Head-to-head comparative studies are needed 
to determine the possible clinical and cost beneﬁ  ts of can-
nabinoid therapy.
Nabilone has recently been approved by the Food and 
Drug Administration (FDA) for the treatment of nausea and 
vomiting associated with chemotherapy in cancer patients 
who fail to respond adequately to conventional antiemetic 
treatments (Waknine 2006). Nabilone is typically given 
twice daily owing to its long duration of action (8–12 hours). 
The usual daily dosage of nabilone is 1–2 mg bid, with the 
ﬁ  rst dose given 1–3 hours before administration of chemo-
therapy; the maximum recommended daily dosage is 6 mg 
daily divided bid or tid. Similar to several medications, there 
is a therapeutic window for nabilone, at which maximum 
beneﬁ  t is obtained without intolerable side effects. Thus, 
treatment should be initiated with the lowest starting dose, 
and the dose should be increased based on patient response 
to minimize side effects. Patients often beneﬁ  t from one dose 
the evening before chemotherapy, and another dose 1 to 3 
hours pre-chemotherapy.
The most commonly occurring side effects of nabilone 
therapy are drowsiness, vertigo, dry mouth, euphoria, ataxia, 
headache, and concentration difﬁ  culties. Generally, the side 
effects are mild in intensity and temporary in duration. Toler-
ance to the CNS effects of nabilone, such as drowsiness and 
vertigo, develops rapidly. Assessing patients prior to initiat-
ing therapy can assist in reducing side effects and increasing 
tolerability. Patients should be warned about taking nabilone 
with alcohol, sedatives, hypnotics, or other psychoactive 
substances due to the potential for augmentation of CNS 
effects. Nabilone should be used with caution in patients 
with current or past history of psychiatric disorders, as well 
as those with a history of substance abuse. Both short- and 
long-term cognitive effects of cannabinoids are not well 
described under therapeutic conditions, but based on the 
well-known cognitive effects of recreational cannabis use, 
careful monitoring is advised. Severe cognitive impairment 
from therapeutic use of nabilone has not been described. The 
response to and tolerance of nabilone varies from individual 
to individual; thus, patients should remain under the supervi-
sion of a responsible adult during initial use of the medica-
tion. Drug–drug interactions may be a concern in cancer 
patients who might be taking several different medications 
concurrently. Nabilone does not induce cytochrome P450 
3A4 isoenzymes and lacks signiﬁ  cant 3A4 inhibitory effect 
(Nahas et al 2002). Thus, interactions with drugs metabolized 
via this pathway, such as macrolide antibiotics, calcium chan-
nel blockers, and others, are unlikely.
In summary, results from early clinical trials demon-
strated the efﬁ  cacy of nabilone in reducing the frequency 
of vomiting and lessening the severity of nausea in cancer 
patients with severe and/or refractory CINV. Importantly, 
nabilone was effective across the 5 days of chemotherapy 
in reducing both vomiting episodes and nausea severity, 
speciﬁ  c areas in which other antiemetic agents fail to provide 
adequate patient relief. While the incidence of side effects 
with nabilone therapy is higher than with active controls, 
the side effects generally are mild to moderate in intensity, 
resolve over time, and do not impact patient preference for 
nabilone over other medications. To minimize the risk for 
and severity of side effects and improve patient tolerance, 
it is important to “start low and go slow” in terms of initial 
dose and dose titration. While studies comparing nabilone to 
modern antiemetics are anticipated, nabilone is an additional 
tool in the oncologist’s efforts to control nausea and improve 
the tolerability of potentially life-saving chemotherapy.
Potential uses of nabilone in cancer 
patients
A better understanding of the mechanism of action of endo-
cannabinoids has led to investigation of the potential beneﬁ  t 
of pharmaceutical cannabinoids for the treatment of other 
symptoms and side effects of therapy and diseases. Published 
evidence supports the possible use of nabilone and other 
cannabinoids in cancer patients to treat radiotherapy-induced 
nausea, depression and anxiety, sleep disorders, and pain, Therapeutics and Clinical Risk Management 2008:4(1) 105
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particularly neuropathic pain (Fabre and McLendon 1981; 
Priestman et al 1984, 1987; Kalant 2001; Croxford 2003; 
Ben Amar 2006; Berlach et al 2006; Wissel et al 2006). The 
efﬁ  cacy of dronabinol to treat cachexia/wasting in AIDS 
patients suggested that cannabinoids may be useful for treat-
ing this syndrome in cancer patients, although this has not 
been demonstrated in a recent trial (Strasser et al 2006).
Pain is a common symptom among cancer patients, affect-
ing 18% to 49% at diagnosis and nearly 75% of those patients 
with advanced disease (Daut and Cleeland 1982; Bonica 
1990). Preclinical data support the efﬁ  cacy of cannabinoids 
in a broad range of pain models, including neuropathic and 
chronic pain, for which there is signiﬁ  cant evidence (Mack 
and Joy 2001). Up-regulation of CB1 receptors are key to 
the analgesic effects of cannabinoids in both chronic and 
neuropathic pain, and CB2 receptors also appear to play an 
important role (Croxford 2003).
Data are accumulating for the efﬁ  cacy of pain manage-
ment in humans. Notcutt and colleagues reported that can-
nabinoid therapy reduced either one or both of two primary 
symptoms by 50% in 34 patients with chronic pain, most 
of which was neuropathic pain (Notcutt 2004). Although a 
retrospective chart review was conducted in patients with 
chronic non-cancer pain, the ﬁ  ndings suggest nabilone might 
be a useful adjunct in the treatment of chronic pain, as well 
as other symptoms, in a variety of chronic pain patients 
(Berlach et al 2006). Nearly 1 of every 2 patients experienced 
pain relief, and complete pain relief was documented in one 
fourth of the study cohort. Of note, only one patient had 
tried fewer than 5 different regimens to treat pain prior to 
receiving nabilone. Additional beneﬁ  ts of nabilone therapy 
observed in this study included decreased sleep disturbances, 
reduced severity of nausea and frequency of vomiting, and 
improved appetite.
Neuropathic pain poses substantial treatment challenges 
as it is often unresponsive to conventional therapy (Shake-
speare et al 2003). Efﬁ  cacy of cannabinoids in the treatment 
of non-malignant neuropathic pain might indicate the useful-
ness of nabilone therapy in cancer patients with neuropathic 
pain syndromes. Recently, Wissel and associates reported 
a signiﬁ  cant (p   0.05) decrease in spasticity-associated 
pain with nabilone therapy when compared with placebo in 
patients with upper motor neuron syndrome. (Wissel et al 
2006). All patients suffered from chronic spasticity-related 
pain refractory to medications frequently used to treat neu-
ropathic pain. Nabilone was initiated at a dosage of 0.5 mg 
daily, which was increased to 1 mg per day after 1 week. 
Patients continued therapy at this dosage for 3 additional 
weeks. At the end of 4 weeks of nabilone therapy, patients 
experienced a median decrease of 2 points on the 11-Point-
Box-Text. Nabilone was well tolerated, and most side 
effects were mild in intensity. The investigators point to the 
anti-inﬂ  ammatory and neuroprotective effects as a possible 
explanation for the beneﬁ  ts of nabilone in their study.
Several studies are currently underway, examining the 
efﬁ  cacy and safety of nabilone for the treatment of neu-
ropathic pain in various patient populations, as well as its 
effects on sleep and other symptoms. Results of these stud-
ies may further the understanding of nabilone and its role 
in cancer patients.
Summary
Cannabinoids have been shown to have effects in a variety 
of clinical syndromes, including CINV. Nabilone, a newly 
approved synthetic cannabinoid agonist, has a long history 
of use as an anti-emetic agent has proven to be effective 
in patients with CINV. Nabilone may have a role in those 
patients whose nausea and emesis is not adequately controlled 
by 5-HT3 receptor antagonists and aprepitant. Nabilone may 
also be considered in patients with anticipatory nausea, as 
seen in pre-clinical studies. Further study of nabilone as 
rescue or adjuvant therapy is warranted in these areas. There 
is also a growing body of literature to suggest additional 
beneﬁ  ts in cancer patients, including pain control. Continued 
study of this class of drugs may yield more indications, not 
only in patients with malignancies, but also in the wider ﬁ  eld 
of non-malignant diseases.
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